Open Collections

UBC Faculty Research and Publications

New drugs V Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 34 reviews the new drugs orlistat, raloxifene, and spironolactone. Conclusions: In obese patients orlistat in combination with a low-fat diet (<30% of calories) reduces body weight by 3.3 kg in the first year as compared to placebo. Adverse gastrointestinal effects are frequent and it is unknown whether orlistat affects morbidity and mortality linked to obesity. Raloxifene reduced radiologic vertebral collapse in both the primary (ARR = 2.2%) and secondary prevention (ARR = 6.5%) settings, but had no effect on non-vertebral fractures (including hip fractures). Benefits for reduction in painful vertebral collapse and reduction in early breast cancer were small and of a similar magnitude to the harm of increased thromboembolic events.Spironolactone added to standard therapy represents a significant advance in the management of severe CHF.

Item Metadata

Title
New drugs V
Alternate Title
Therapeutics Letter 34
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
2000-04
Description
Therapeutics Letter 34 reviews the new drugs orlistat, raloxifene, and spironolactone. Conclusions: In obese patients orlistat in combination with a low-fat diet (<30% of calories) reduces body weight by 3.3 kg in the first year as compared to placebo. Adverse gastrointestinal effects are frequent and it is unknown whether orlistat affects morbidity and mortality linked to obesity. Raloxifene reduced radiologic vertebral collapse in both the primary (ARR = 2.2%) and secondary prevention (ARR = 6.5%) settings, but had no effect on non-vertebral fractures (including hip fractures). Benefits for reduction in painful vertebral collapse and reduction in early breast cancer were small and of a similar magnitude to the harm of increased thromboembolic events.Spironolactone added to standard therapy represents a significant advance in the management of severe CHF.
Subject
Body Weight; Breast Neoplasms; Morbidity; Obesity; Orlistat; Raloxifene Hydrochloride; Spironolactone
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433613
URI
http://hdl.handle.net/2429/85023
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International